Illumina, Inc.
Illumina, Inc. (ILMN) Stock Competitors & Peer Comparison
See (ILMN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ILMN | $108.71 | -1.06% | 17.2B | -17.88 | -$6.08 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.57% |
| TMO | $482.16 | -0.58% | 182.1B | 27.85 | $17.32 | +0.34% |
| DHR | $206.85 | +1.93% | 148.2B | 43.94 | $4.71 | +0.57% |
| IDXX | $573.07 | +1.16% | 46.1B | 52.96 | $10.82 | N/A |
| A | $119.84 | +0.25% | 34B | 29.51 | $4.06 | +0.81% |
| IQV | $194.55 | -1.62% | 33.1B | 28.24 | $6.89 | N/A |
| MTD | $1,266.10 | +0.40% | 26.4B | 31.66 | $40.07 | N/A |
| DGX | $167.93 | +0.05% | 18.8B | 20.13 | $8.34 | +1.85% |
| NTRA | $135.84 | -1.57% | 18.5B | -91.78 | -$1.48 | N/A |
Stock Comparison
ILMN vs DHR-PB Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, ILMN is priced at $108.71, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, ILMN's ROE is -0.46%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, ILMN is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check DHR-PB's competition here
ILMN vs TMO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, TMO has a market cap of 182.1B. Regarding current trading prices, ILMN is priced at $108.71, while TMO trades at $482.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas TMO's P/E ratio is 27.85. In terms of profitability, ILMN's ROE is -0.46%, compared to TMO's ROE of +0.13%. Regarding short-term risk, ILMN is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check TMO's competition here
ILMN vs DHR Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, DHR has a market cap of 148.2B. Regarding current trading prices, ILMN is priced at $108.71, while DHR trades at $206.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas DHR's P/E ratio is 43.94. In terms of profitability, ILMN's ROE is -0.46%, compared to DHR's ROE of +0.07%. Regarding short-term risk, ILMN is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check DHR's competition here
ILMN vs IDXX Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, IDXX has a market cap of 46.1B. Regarding current trading prices, ILMN is priced at $108.71, while IDXX trades at $573.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas IDXX's P/E ratio is 52.96. In terms of profitability, ILMN's ROE is -0.46%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, ILMN is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check IDXX's competition here
ILMN vs A Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, A has a market cap of 34B. Regarding current trading prices, ILMN is priced at $108.71, while A trades at $119.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas A's P/E ratio is 29.51. In terms of profitability, ILMN's ROE is -0.46%, compared to A's ROE of +0.19%. Regarding short-term risk, ILMN is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check A's competition here
ILMN vs IQV Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, IQV has a market cap of 33.1B. Regarding current trading prices, ILMN is priced at $108.71, while IQV trades at $194.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas IQV's P/E ratio is 28.24. In terms of profitability, ILMN's ROE is -0.46%, compared to IQV's ROE of +0.20%. Regarding short-term risk, ILMN is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check IQV's competition here
ILMN vs MTD Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, MTD has a market cap of 26.4B. Regarding current trading prices, ILMN is priced at $108.71, while MTD trades at $1,266.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas MTD's P/E ratio is 31.66. In terms of profitability, ILMN's ROE is -0.46%, compared to MTD's ROE of +1.21%. Regarding short-term risk, ILMN is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check MTD's competition here
ILMN vs DGX Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, DGX has a market cap of 18.8B. Regarding current trading prices, ILMN is priced at $108.71, while DGX trades at $167.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas DGX's P/E ratio is 20.13. In terms of profitability, ILMN's ROE is -0.46%, compared to DGX's ROE of +0.14%. Regarding short-term risk, ILMN is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check DGX's competition here
ILMN vs NTRA Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, NTRA has a market cap of 18.5B. Regarding current trading prices, ILMN is priced at $108.71, while NTRA trades at $135.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas NTRA's P/E ratio is -91.78. In terms of profitability, ILMN's ROE is -0.46%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, ILMN is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check NTRA's competition here
ILMN vs WAT Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, WAT has a market cap of 18.1B. Regarding current trading prices, ILMN is priced at $108.71, while WAT trades at $303.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas WAT's P/E ratio is 27.51. In terms of profitability, ILMN's ROE is -0.46%, compared to WAT's ROE of +0.39%. Regarding short-term risk, ILMN is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check WAT's competition here
ILMN vs ICLR Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ICLR has a market cap of 15B. Regarding current trading prices, ILMN is priced at $108.71, while ICLR trades at $185.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ICLR's P/E ratio is 19.07. In terms of profitability, ILMN's ROE is -0.46%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, ILMN is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ICLR's competition here
ILMN vs PKI Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, ILMN is priced at $108.71, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas PKI's P/E ratio is 41.45. In terms of profitability, ILMN's ROE is -0.46%, compared to PKI's ROE of +0.04%. Regarding short-term risk, ILMN is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check PKI's competition here
ILMN vs MEDP Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, MEDP has a market cap of 12.6B. Regarding current trading prices, ILMN is priced at $108.71, while MEDP trades at $447.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas MEDP's P/E ratio is 33.28. In terms of profitability, ILMN's ROE is -0.46%, compared to MEDP's ROE of +0.68%. Regarding short-term risk, ILMN is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check MEDP's competition here
ILMN vs RVTY Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, RVTY has a market cap of 11.1B. Regarding current trading prices, ILMN is priced at $108.71, while RVTY trades at $94.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas RVTY's P/E ratio is 41.07. In terms of profitability, ILMN's ROE is -0.46%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, ILMN is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check RVTY's competition here
ILMN vs QGEN Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, QGEN has a market cap of 11.1B. Regarding current trading prices, ILMN is priced at $108.71, while QGEN trades at $51.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas QGEN's P/E ratio is 121.57. In terms of profitability, ILMN's ROE is -0.46%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, ILMN is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check QGEN's competition here
ILMN vs TEM Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, TEM has a market cap of 9.8B. Regarding current trading prices, ILMN is priced at $108.71, while TEM trades at $58.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas TEM's P/E ratio is -11.30. In terms of profitability, ILMN's ROE is -0.46%, compared to TEM's ROE of -5.31%. Regarding short-term risk, ILMN is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check TEM's competition here
ILMN vs EXAS Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, EXAS has a market cap of 9B. Regarding current trading prices, ILMN is priced at $108.71, while EXAS trades at $47.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas EXAS's P/E ratio is -8.60. In terms of profitability, ILMN's ROE is -0.46%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, ILMN is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check EXAS's competition here
ILMN vs CRL Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CRL has a market cap of 8.8B. Regarding current trading prices, ILMN is priced at $108.71, while CRL trades at $178.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CRL's P/E ratio is -297.18. In terms of profitability, ILMN's ROE is -0.46%, compared to CRL's ROE of -0.01%. Regarding short-term risk, ILMN is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check CRL's competition here
ILMN vs GH Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, GH has a market cap of 5.4B. Regarding current trading prices, ILMN is priced at $108.71, while GH trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas GH's P/E ratio is -12.78. In terms of profitability, ILMN's ROE is -0.46%, compared to GH's ROE of +3.69%. Regarding short-term risk, ILMN is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check GH's competition here
ILMN vs SYNH Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, ILMN is priced at $108.71, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas SYNH's P/E ratio is 61.40. In terms of profitability, ILMN's ROE is -0.46%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, ILMN is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check SYNH's competition here
ILMN vs RDNT Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, ILMN is priced at $108.71, while RDNT trades at $56.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas RDNT's P/E ratio is -131.49. In terms of profitability, ILMN's ROE is -0.46%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, ILMN is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check RDNT's competition here
ILMN vs SHC Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, SHC has a market cap of 3.4B. Regarding current trading prices, ILMN is priced at $108.71, while SHC trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas SHC's P/E ratio is 134.89. In terms of profitability, ILMN's ROE is -0.46%, compared to SHC's ROE of +0.06%. Regarding short-term risk, ILMN is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check SHC's competition here
ILMN vs OLK Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, ILMN is priced at $108.71, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas OLK's P/E ratio is -96.59. In terms of profitability, ILMN's ROE is -0.46%, compared to OLK's ROE of -0.07%. Regarding short-term risk, ILMN is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check OLK's competition here
ILMN vs TWST Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, TWST has a market cap of 2.1B. Regarding current trading prices, ILMN is priced at $108.71, while TWST trades at $34.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas TWST's P/E ratio is -10.51. In terms of profitability, ILMN's ROE is -0.46%, compared to TWST's ROE of -0.41%. Regarding short-term risk, ILMN is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check TWST's competition here
ILMN vs VIVO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, ILMN is priced at $108.71, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas VIVO's P/E ratio is 21.09. In terms of profitability, ILMN's ROE is -0.46%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, ILMN is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check VIVO's competition here
ILMN vs GRAL Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, GRAL has a market cap of 1.2B. Regarding current trading prices, ILMN is priced at $108.71, while GRAL trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas GRAL's P/E ratio is -0.57. In terms of profitability, ILMN's ROE is -0.46%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, ILMN is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check GRAL's competition here
ILMN vs OPK Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, ILMN is priced at $108.71, while OPK trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas OPK's P/E ratio is -22.50. In terms of profitability, ILMN's ROE is -0.46%, compared to OPK's ROE of -0.03%. Regarding short-term risk, ILMN is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check OPK's competition here
ILMN vs NEOG Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, NEOG has a market cap of 1B. Regarding current trading prices, ILMN is priced at $108.71, while NEOG trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas NEOG's P/E ratio is -2.17. In terms of profitability, ILMN's ROE is -0.46%, compared to NEOG's ROE of -0.41%. Regarding short-term risk, ILMN is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check NEOG's competition here
ILMN vs CDNA Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CDNA has a market cap of 708.3M. Regarding current trading prices, ILMN is priced at $108.71, while CDNA trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CDNA's P/E ratio is 11.36. In terms of profitability, ILMN's ROE is -0.46%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, ILMN is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check CDNA's competition here
ILMN vs GRALV Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, ILMN is priced at $108.71, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas GRALV's P/E ratio is N/A. In terms of profitability, ILMN's ROE is -0.46%, compared to GRALV's ROE of N/A. Regarding short-term risk, ILMN is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check GRALV's competition here
ILMN vs FLGT Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, FLGT has a market cap of 534.9M. Regarding current trading prices, ILMN is priced at $108.71, while FLGT trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas FLGT's P/E ratio is -13.21. In terms of profitability, ILMN's ROE is -0.46%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, ILMN is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check FLGT's competition here
ILMN vs LAB Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, LAB has a market cap of 528M. Regarding current trading prices, ILMN is priced at $108.71, while LAB trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas LAB's P/E ratio is -4.34. In terms of profitability, ILMN's ROE is -0.46%, compared to LAB's ROE of -0.28%. Regarding short-term risk, ILMN is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check LAB's competition here
ILMN vs PSNL Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, PSNL has a market cap of 492.9M. Regarding current trading prices, ILMN is priced at $108.71, while PSNL trades at $5.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas PSNL's P/E ratio is -4.33. In terms of profitability, ILMN's ROE is -0.46%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, ILMN is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check PSNL's competition here
ILMN vs CSTL Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CSTL has a market cap of 468.6M. Regarding current trading prices, ILMN is priced at $108.71, while CSTL trades at $16.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CSTL's P/E ratio is -85.42. In terms of profitability, ILMN's ROE is -0.46%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, ILMN is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check CSTL's competition here
ILMN vs CO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, ILMN is priced at $108.71, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CO's P/E ratio is 5.06. In terms of profitability, ILMN's ROE is -0.46%, compared to CO's ROE of +0.11%. Regarding short-term risk, ILMN is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check CO's competition here
ILMN vs MYGN Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, MYGN has a market cap of 377.9M. Regarding current trading prices, ILMN is priced at $108.71, while MYGN trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas MYGN's P/E ratio is -3.66. In terms of profitability, ILMN's ROE is -0.46%, compared to MYGN's ROE of -0.14%. Regarding short-term risk, ILMN is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check MYGN's competition here
ILMN vs STIM Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, STIM has a market cap of 295.5M. Regarding current trading prices, ILMN is priced at $108.71, while STIM trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas STIM's P/E ratio is -3.39. In terms of profitability, ILMN's ROE is -0.46%, compared to STIM's ROE of -2.09%. Regarding short-term risk, ILMN is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check STIM's competition here
ILMN vs FLDM Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, ILMN is priced at $108.71, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas FLDM's P/E ratio is -4.74. In terms of profitability, ILMN's ROE is -0.46%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, ILMN is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check FLDM's competition here
ILMN vs XGN Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, XGN has a market cap of 184.7M. Regarding current trading prices, ILMN is priced at $108.71, while XGN trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas XGN's P/E ratio is -10.06. In terms of profitability, ILMN's ROE is -0.46%, compared to XGN's ROE of -1.36%. Regarding short-term risk, ILMN is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check XGN's competition here
ILMN vs ACRS Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ACRS has a market cap of 167.8M. Regarding current trading prices, ILMN is priced at $108.71, while ACRS trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ACRS's P/E ratio is -0.97. In terms of profitability, ILMN's ROE is -0.46%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, ILMN is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ACRS's competition here
ILMN vs NEO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, NEO has a market cap of 135.1M. Regarding current trading prices, ILMN is priced at $108.71, while NEO trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas NEO's P/E ratio is -8.61. In terms of profitability, ILMN's ROE is -0.46%, compared to NEO's ROE of -0.12%. Regarding short-term risk, ILMN is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check NEO's competition here
ILMN vs GTH Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, ILMN is priced at $108.71, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas GTH's P/E ratio is -1.11. In terms of profitability, ILMN's ROE is -0.46%, compared to GTH's ROE of -1.01%. Regarding short-term risk, ILMN is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check GTH's competition here
ILMN vs MDXH Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, MDXH has a market cap of 122.1M. Regarding current trading prices, ILMN is priced at $108.71, while MDXH trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas MDXH's P/E ratio is -2.37. In terms of profitability, ILMN's ROE is -0.46%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, ILMN is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check MDXH's competition here
ILMN vs GENE Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, ILMN is priced at $108.71, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas GENE's P/E ratio is -38.25. In terms of profitability, ILMN's ROE is -0.46%, compared to GENE's ROE of -3.62%. Regarding short-term risk, ILMN is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check GENE's competition here
ILMN vs SERA Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, SERA has a market cap of 106.4M. Regarding current trading prices, ILMN is priced at $108.71, while SERA trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas SERA's P/E ratio is -3.09. In terms of profitability, ILMN's ROE is -0.46%, compared to SERA's ROE of -0.51%. Regarding short-term risk, ILMN is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check SERA's competition here
ILMN vs PRENW Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, PRENW has a market cap of 105.9M. Regarding current trading prices, ILMN is priced at $108.71, while PRENW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas PRENW's P/E ratio is N/A. In terms of profitability, ILMN's ROE is -0.46%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, ILMN is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check PRENW's competition here
ILMN vs PRE Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, PRE has a market cap of 104.4M. Regarding current trading prices, ILMN is priced at $108.71, while PRE trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas PRE's P/E ratio is -2.10. In terms of profitability, ILMN's ROE is -0.46%, compared to PRE's ROE of -0.28%. Regarding short-term risk, ILMN is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check PRE's competition here
ILMN vs ATLN Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ATLN has a market cap of 101.1M. Regarding current trading prices, ILMN is priced at $108.71, while ATLN trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ATLN's P/E ratio is -0.44. In terms of profitability, ILMN's ROE is -0.46%, compared to ATLN's ROE of -42.96%. Regarding short-term risk, ILMN is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ATLN's competition here
ILMN vs VNRX Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, VNRX has a market cap of 72.8M. Regarding current trading prices, ILMN is priced at $108.71, while VNRX trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas VNRX's P/E ratio is -2.59. In terms of profitability, ILMN's ROE is -0.46%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, ILMN is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check VNRX's competition here
ILMN vs NOTV Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, NOTV has a market cap of 69.7M. Regarding current trading prices, ILMN is priced at $108.71, while NOTV trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas NOTV's P/E ratio is -0.65. In terms of profitability, ILMN's ROE is -0.46%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, ILMN is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check NOTV's competition here
ILMN vs BDSX Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BDSX has a market cap of 56.9M. Regarding current trading prices, ILMN is priced at $108.71, while BDSX trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BDSX's P/E ratio is -1.44. In terms of profitability, ILMN's ROE is -0.46%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, ILMN is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check BDSX's competition here
ILMN vs STRRP Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, STRRP has a market cap of 29.1M. Regarding current trading prices, ILMN is priced at $108.71, while STRRP trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas STRRP's P/E ratio is -4.51. In terms of profitability, ILMN's ROE is -0.46%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, ILMN is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check STRRP's competition here
ILMN vs AKU Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, ILMN is priced at $108.71, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas AKU's P/E ratio is -0.13. In terms of profitability, ILMN's ROE is -0.46%, compared to AKU's ROE of -5.32%. Regarding short-term risk, ILMN is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check AKU's competition here
ILMN vs DRIO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, DRIO has a market cap of 24.2M. Regarding current trading prices, ILMN is priced at $108.71, while DRIO trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas DRIO's P/E ratio is -0.99. In terms of profitability, ILMN's ROE is -0.46%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, ILMN is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check DRIO's competition here
ILMN vs PRPO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, PRPO has a market cap of 22.3M. Regarding current trading prices, ILMN is priced at $108.71, while PRPO trades at $14.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas PRPO's P/E ratio is -7.17. In terms of profitability, ILMN's ROE is -0.46%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, ILMN is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check PRPO's competition here
ILMN vs CEMI Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, ILMN is priced at $108.71, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CEMI's P/E ratio is -0.63. In terms of profitability, ILMN's ROE is -0.46%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, ILMN is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check CEMI's competition here
ILMN vs ENZ Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, ILMN is priced at $108.71, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ENZ's P/E ratio is -2.24. In terms of profitability, ILMN's ROE is -0.46%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, ILMN is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ENZ's competition here
ILMN vs PMD Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, ILMN is priced at $108.71, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas PMD's P/E ratio is -5.24. In terms of profitability, ILMN's ROE is -0.46%, compared to PMD's ROE of -0.33%. Regarding short-term risk, ILMN is less volatile compared to PMD. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check PMD's competition here
ILMN vs ME Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, ILMN is priced at $108.71, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ME's P/E ratio is -0.03. In terms of profitability, ILMN's ROE is -0.46%, compared to ME's ROE of -3.99%. Regarding short-term risk, ILMN is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ME's competition here
ILMN vs ADVB Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ADVB has a market cap of 11.7M. Regarding current trading prices, ILMN is priced at $108.71, while ADVB trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ADVB's P/E ratio is -3.37. In terms of profitability, ILMN's ROE is -0.46%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, ILMN is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ADVB's competition here
ILMN vs INBS Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, INBS has a market cap of 11M. Regarding current trading prices, ILMN is priced at $108.71, while INBS trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas INBS's P/E ratio is -1.20. In terms of profitability, ILMN's ROE is -0.46%, compared to INBS's ROE of -1.72%. Regarding short-term risk, ILMN is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check INBS's competition here
ILMN vs BNGO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BNGO has a market cap of 10.6M. Regarding current trading prices, ILMN is priced at $108.71, while BNGO trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BNGO's P/E ratio is -0.06. In terms of profitability, ILMN's ROE is -0.46%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, ILMN is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check BNGO's competition here
ILMN vs BIAFW Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BIAFW has a market cap of 10.4M. Regarding current trading prices, ILMN is priced at $108.71, while BIAFW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BIAFW's P/E ratio is N/A. In terms of profitability, ILMN's ROE is -0.46%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, ILMN is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check BIAFW's competition here
ILMN vs CNTG Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, ILMN is priced at $108.71, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CNTG's P/E ratio is -0.23. In terms of profitability, ILMN's ROE is -0.46%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, ILMN is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check CNTG's competition here
ILMN vs BIAF Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BIAF has a market cap of 9.2M. Regarding current trading prices, ILMN is priced at $108.71, while BIAF trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BIAF's P/E ratio is -0.46. In terms of profitability, ILMN's ROE is -0.46%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, ILMN is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check BIAF's competition here
ILMN vs BGLC Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BGLC has a market cap of 8M. Regarding current trading prices, ILMN is priced at $108.71, while BGLC trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BGLC's P/E ratio is -3.75. In terms of profitability, ILMN's ROE is -0.46%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, ILMN is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check BGLC's competition here
ILMN vs MYNZ Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, MYNZ has a market cap of 7.1M. Regarding current trading prices, ILMN is priced at $108.71, while MYNZ trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas MYNZ's P/E ratio is -0.08. In terms of profitability, ILMN's ROE is -0.46%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, ILMN is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check MYNZ's competition here
ILMN vs TRIB Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, TRIB has a market cap of 7M. Regarding current trading prices, ILMN is priced at $108.71, while TRIB trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas TRIB's P/E ratio is -0.37. In terms of profitability, ILMN's ROE is -0.46%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, ILMN is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check TRIB's competition here
ILMN vs STRR Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, STRR has a market cap of 6.8M. Regarding current trading prices, ILMN is priced at $108.71, while STRR trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas STRR's P/E ratio is -0.70. In terms of profitability, ILMN's ROE is -0.46%, compared to STRR's ROE of -0.24%. Regarding short-term risk, ILMN is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check STRR's competition here
ILMN vs BNR Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BNR has a market cap of 6.3M. Regarding current trading prices, ILMN is priced at $108.71, while BNR trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BNR's P/E ratio is -1.80. In terms of profitability, ILMN's ROE is -0.46%, compared to BNR's ROE of -0.39%. Regarding short-term risk, ILMN is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check BNR's competition here
ILMN vs NVTA Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, ILMN is priced at $108.71, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas NVTA's P/E ratio is -0.00. In terms of profitability, ILMN's ROE is -0.46%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, ILMN is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check NVTA's competition here
ILMN vs LMDXW Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, ILMN is priced at $108.71, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, ILMN's ROE is -0.46%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, ILMN is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check LMDXW's competition here
ILMN vs LMDX Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, ILMN is priced at $108.71, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas LMDX's P/E ratio is -0.01. In terms of profitability, ILMN's ROE is -0.46%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, ILMN is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check LMDX's competition here
ILMN vs NDRA Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, NDRA has a market cap of 4.4M. Regarding current trading prices, ILMN is priced at $108.71, while NDRA trades at $5.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas NDRA's P/E ratio is 0.01. In terms of profitability, ILMN's ROE is -0.46%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, ILMN is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check NDRA's competition here
ILMN vs CHEK Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, CHEK has a market cap of 4.2M. Regarding current trading prices, ILMN is priced at $108.71, while CHEK trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas CHEK's P/E ratio is -0.34. In terms of profitability, ILMN's ROE is -0.46%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, ILMN is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check CHEK's competition here
ILMN vs DMTK Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, ILMN is priced at $108.71, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas DMTK's P/E ratio is -0.04. In terms of profitability, ILMN's ROE is -0.46%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, ILMN is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check DMTK's competition here
ILMN vs AWH Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, ILMN is priced at $108.71, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas AWH's P/E ratio is -0.09. In terms of profitability, ILMN's ROE is -0.46%, compared to AWH's ROE of +4.66%. Regarding short-term risk, ILMN is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check AWH's competition here
ILMN vs ISPC Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, ISPC has a market cap of 2.6M. Regarding current trading prices, ILMN is priced at $108.71, while ISPC trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas ISPC's P/E ratio is -0.09. In terms of profitability, ILMN's ROE is -0.46%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, ILMN is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check ISPC's competition here
ILMN vs APDN Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, APDN has a market cap of 2.5M. Regarding current trading prices, ILMN is priced at $108.71, while APDN trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas APDN's P/E ratio is N/A. In terms of profitability, ILMN's ROE is -0.46%, compared to APDN's ROE of -2.81%. Regarding short-term risk, ILMN is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check APDN's competition here
ILMN vs SQL Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, ILMN is priced at $108.71, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas SQL's P/E ratio is -0.40. In terms of profitability, ILMN's ROE is -0.46%, compared to SQL's ROE of +10.89%. Regarding short-term risk, ILMN is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check SQL's competition here
ILMN vs HTGM Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, ILMN is priced at $108.71, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas HTGM's P/E ratio is -0.03. In terms of profitability, ILMN's ROE is -0.46%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, ILMN is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check HTGM's competition here
ILMN vs BIOC Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, ILMN is priced at $108.71, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas BIOC's P/E ratio is -0.01. In terms of profitability, ILMN's ROE is -0.46%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, ILMN is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check BIOC's competition here
ILMN vs TTOO Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, TTOO has a market cap of 426.3K. Regarding current trading prices, ILMN is priced at $108.71, while TTOO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas TTOO's P/E ratio is -0.51. In terms of profitability, ILMN's ROE is -0.46%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, ILMN is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check TTOO's competition here
ILMN vs OPGN Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, OPGN has a market cap of 392.7K. Regarding current trading prices, ILMN is priced at $108.71, while OPGN trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas OPGN's P/E ratio is N/A. In terms of profitability, ILMN's ROE is -0.46%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, ILMN is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check OPGN's competition here
ILMN vs SQLLW Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, ILMN is priced at $108.71, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, ILMN's ROE is -0.46%, compared to SQLLW's ROE of -42.96%. Regarding short-term risk, ILMN is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check SQLLW's competition here
ILMN vs OCDX Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, ILMN is priced at $108.71, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas OCDX's P/E ratio is -42.28. In terms of profitability, ILMN's ROE is -0.46%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, ILMN is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check OCDX's competition here
ILMN vs MEUSW Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, ILMN is priced at $108.71, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas MEUSW's P/E ratio is N/A. In terms of profitability, ILMN's ROE is -0.46%, compared to MEUSW's ROE of -3.99%. Regarding short-term risk, ILMN is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for ILMN.Check MEUSW's competition here
ILMN vs DHR-PA Comparison July 2025
ILMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 17.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, ILMN is priced at $108.71, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of -17.88, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, ILMN's ROE is -0.46%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, ILMN is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for ILMN.Check DHR-PA's competition here